Xalatan

Selected form

Latanoprost

Method of action: Antiglaucomatous, Intraocular Pressure Lowering, Ophthalmologicals

Treatment option: Hypertension, Glaucoma

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xalatan

What is Xalatan?

Xalatan is a prescription ophthalmic solution administered as sterile eye drops that functions as an ocular hypotensive agent, primarily used to lower pressure inside the eye. Its medicinal identity is defined by its single active ingredient, Latanoprost, which belongs to the prostaglandin analogue (PGA) pharmacological class. This compound is characterized as a potent ocular hypotensive agent used for long-term pressure control.

What Type of Medicine is Xalatan (Latanoprost)?

Xalatan is categorized as a prostaglandin analogue of Prostaglandin F2alpha. This classification is significant because it defines the drug's mechanism, which involves enhancing fluid drainage from the eye rather than decreasing fluid production. This distinction provides a pathway for pressure management in adults with conditions that cause elevated intraocular pressure.

Composition and Origin: Is Latanoprost Synthetic?

The active ingredient, Latanoprost, is a synthetic compound. It is formulated as an isopropyl ester prodrug, meaning it is administered in an inactive chemical form to maximize absorption through the cornea before being converted via hydrolysis into the active metabolite, Latanoprost acid. The product is a single-ingredient solution contained within an aqueous base necessary for topical use.

Primary Purpose: How Does Xalatan Help the Eye?

The primary purpose of Xalatan is to achieve sustained reduction of elevated intraocular pressure (IOP). It accomplishes this by acting on specific receptors to increase aqueous humor outflow through the uveoscleral pathway. This action is utilized to mitigate the potential damage to the optic nerve associated with chronic high pressure, providing targeted pressure relief.

Regulatory References

What side effects are possible with Xalatan ?

Possible Side Effects and Safety Information

Xalatan (latanoprost ophthalmic solution) is associated with several officially documented adverse reactions, primarily affecting the eyes and surrounding tissues.

Common and Ocular Adverse Reactions

The most frequently reported side effects, occurring in 5% to 15% of patients, are local and include eye irritation (such as burning, stinging, itching, or foreign body sensation), conjunctival hyperemia (eye redness), blurred vision, punctate keratitis (irritation on the clear front surface of the eye), and increased pigmentation of the iris.

Pigmentation Changes and Eyelash Alterations

Latanoprost may cause a gradual increase in brown pigmentation of the iris, which is generally considered permanent even after discontinuing the medication. Patients should be informed of the potential for this color change, which may result in a cosmetic difference if only one eye is treated. The medication may also cause darkening of the eyelid skin and changes to the eyelashes, including increased length, thickness, and number; these changes are usually reversible upon discontinuation.

Serious Adverse Reactions and Precautions

Serious, though less common, adverse reactions documented in regulatory and postmarketing reports include macular edema (including cystoid macular edema), intraocular inflammation (iritis/uveitis), and herpes simplex keratitis reactivation. The drug should be used with caution in patients with a history of intraocular inflammation or herpetic keratitis, and in specific at-risk populations such as aphakic or pseudophakic patients with a torn posterior lens capsule.

Safety Restrictions

Xalatan is contraindicated in patients with a known hypersensitivity to latanoprost, benzalkonium chloride, or any other components. The medication contains benzalkonium chloride, which can be absorbed by soft contact lenses. Therefore, contact lenses must be removed prior to administration and may be reinserted 15 minutes afterward. Contamination of the multi-dose container tip poses a risk of bacterial keratitis.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Xalatan (Latanoprost) is defined by official regulatory documentation, covering both localized ocular overexposure and accidental systemic ingestion.

Documented Overdose Presentations

Ocular Overexposure: Overdose resulting from placing an excess volume of drops in the eye may present with transient, localized clinical signs. Documented manifestations include slight ocular irritation, conjunctival hyperaemia (redness), and lacrimation (watery eyes). These slight symptoms are generally expected to pass.

Accidental Systemic Ingestion: Accidental swallowing of the ophthalmic solution requires immediate emergency medical attention as explicitly mandated by regulatory authorities. Although a single bottle contains a low dose (125 micrograms) and more than 90% is rapidly metabolized in the liver, high systemic exposure has been associated with manifestations such as nausea, abdominal pain, dizziness, fatigue, and sweating.

Official Emergency Actions and Management

For any instance of accidental ingestion, regulatory information requires seeking emergency medical attention or contacting emergency services immediately. Official regulatory documentation confirms that no specific antidote is known for Latanoprost overdose. Therefore, treatment is limited to providing supportive and symptomatic measures for any documented clinical effects.

Therapeutic Uses of Xalatan

What Xalatan Treats: Main Uses and Benefits

Xalatan (Latanoprost) is a medication commonly used for managing elevated pressure inside the eye, which may assist with preserving vision over time. It is relevant in conditions characterized by high intraocular pressure (IOP) and the functional stress this puts on the eye. The therapeutic use of these drops is centered on regulating the fluid dynamics within the ocular environment.

The primary clinical conditions for which Latanoprost is generally used are Primary Open-Angle Glaucoma and Ocular Hypertension. The therapeutic support offered by the drops helps address this high pressure, which plays a role in managing the progression of vision changes and associated nerve damage. As a core goal, the medication helps maintain a sense of stability by keeping eye pressure within a more manageable range.

This approach to chronic management helps address symptoms that may become intense or disruptive to long-term visual health. The use of Latanoprost supports the patient by maintaining pressure reduction, which may assist with preserving the structural integrity of the optic nerve.

Quick Fact: Management of Pressure Elevation

Xalatan is applied in scenarios where additional management of heightened intraocular pressure is required. It contributes to easing the overall symptom load by supporting the reduction of pressure and may assist with maintaining functional stability of the eye's internal structures.

Regulatory References

NIH MedlinePlus overview of Latanoprost

Eligibility and Restrictions for Use

Who Can and Cannot Use Xalatan?

The eligibility criteria for Xalatan (Latanoprost) are strictly defined by regulatory agencies and determine the specific populations authorized or prohibited from using the eye drops.

Absolute Contraindications

Xalatan must not be used by any patient with a known hypersensitivity or allergy to the active ingredient, latanoprost, or to any other component of the formulation, including the preservative benzalkonium chloride. This is an absolute regulatory restriction.

Conditional Use and Restrictions

Use of Xalatan requires caution or is not recommended in several specific populations, as documented in official labeling:

Existing Eye Conditions: Caution is required for patients with a history of intraocular inflammation (e.g., iritis or uveitis) or a history of herpetic keratitis. The drops are generally avoided in cases of active Herpes Simplex Keratitis.
Lens Status: Patients who are aphakic (no lens) or pseudophakic (artificial lens) with a torn posterior lens capsule should use the medication with caution.
Contact Lens Wearers: Soft contact lenses must be removed before administration and should not be reinserted for 15 minutes after the drops are applied.

Age and Reproductive Status Eligibility

Population	Official Regulatory Status
Adults & Older Adults	Established use; same dosage is generally recommended.
Infants (< 1 year)	Data is limited or unavailable, particularly for preterm infants.
Pregnancy	Not recommended; use only if potential benefit justifies potential risk.
Lactation	Not recommended; a decision should be made to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Latanoprost, the active ingredient, has officially documented interaction patterns focused primarily on ophthalmic co-administration and specific substance classes. Combining Latanoprost with other prostaglandin analogues or derivatives is officially not recommended by regulatory agencies. This restriction is based on a pharmacodynamic interaction risk that may lead to a paradoxical elevation in intraocular pressure, which counteracts the intended therapeutic effect.

A critical timing-based restriction applies when using Xalatan with other topical eye medications. To prevent pharmaceutical incompatibility, including the known precipitation risk with preparations containing Thimerosal, all other ophthalmic drops must be administered at least five minutes apart from Latanoprost. This is a procedural requirement defined in regulatory labeling.

Official documents also address potential interactions with systemic agents. Concomitant use with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), either topical or systemic, is noted to have variable official reports concerning its effect on Latanoprost's IOP-lowering efficacy. Furthermore, regulatory summaries state there are no known interactions with common food or drinks, and no specific CYP-mediated or drug-transporter interactions are cited due to the drug’s minimal systemic exposure.

Mechanism of Action

FP Receptor Agonism and Prodrug Activation

Latanoprost is a synthetic prodrug that is converted into its active metabolite, Latanoprost Acid, via hydrolysis in the ocular tissues. Latanoprost Acid functions as a full agonist (activator) of the Prostaglandin F Receptor (FP Receptor) located in the ciliary muscle. This specific receptor activation is the initial step that triggers the subsequent physiological cascade.

Extracellular Matrix Remodeling and Outflow Enhancement

The activation of the FP receptor leads to an increase in Matrix Metalloproteinases (MMPs), which are enzymes that initiate the breakdown and remodeling of the Extracellular Matrix (ECM) in the interstitial spaces of the ciliary muscle. This structural loosening significantly increases the permeability of the tissue, allowing fluid to drain more easily through the uveoscleral outflow pathway and resulting in the reduction of net intraocular fluid volume.

Mechanism-Dependent Time Dynamics

Because the mechanism requires structural remodeling of the tissue, the full physiological effect of increased fluid drainage is not immediate but typically takes several hours to manifest. This structural reliance also constrains the mechanism, as dosing more frequently than once a day can lead to an attenuated effect on intraocular fluid dynamics due to receptor desensitization.

Dosage and Administration Information

Official Administration Guidelines for Xalatan

Xalatan (latanoprost ophthalmic solution) is administered as a topical ophthalmic medication into the eye. These instructions outline the protocol for its use.

Administration Scope	Detail
Route of Administration	Topical ophthalmic (Eye drops, solution)
Official Dosing Rules	One drop in the affected eye(s) once daily. The dosage must not exceed once daily.
Frequency and Timing	Once daily, preferably in the evening, as this is when the optimal effect is obtained.
Age-Group Rules	The dosage is the same for adults (including the elderly) and the paediatric population (though data is limited for infants under 1 year).
Missed Dose	If one dose is missed, continue with the next dose as normal the following day. Do not use double the amount to make up for the missed dose.

Procedural and Preparation Requirements

Contact Lenses: Soft contact lenses must be removed prior to instillation. They may be reinserted 15 minutes after the administration of the drop.
Multiple Drops: If other topical ophthalmic drugs are being used, they must be administered at least five (5) minutes apart from Xalatan.
Administration Technique: To prevent contamination, the tip of the dispensing container must not contact the eye or surrounding structures.
Special Condition: Immediately following the instillation of each drop, it is recommended to compress the lachrymal sac at the medial canthus (punctal occlusion) for one minute to reduce potential systemic absorption.

Recent Clinical Evidence

Research evidence / Overview of studies for Xalatan

Research Evidence for Elevated Intraocular Pressure

Research evidence for Latanoprost (Xalatan) primarily evaluates its influence on a single measure: elevated intraocular pressure (IOP). The data foundation comes mainly from consistent scientific sources, which describe the evaluation of the medication through standardized study designs.

Research was gathered for studies evaluating Latanoprost in patients with Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT), which are conditions characterized by elevated pressure inside the eye, known as Intraocular Pressure (IOP).

To examine how Latanoprost relates to pressure, researchers relied on a volume of high-quality Randomized Controlled Trials (RCTs). These studies often compared Latanoprost with a non-active solution or to other medications used in clinical practice. The main outcome measured was the change in the IOP from the baseline pressure measurement.

Studies reported patterns of lower IOP measurements across the observed groups compared to baseline. The aggregated data describe patterns related to the measurement of lower IOP over the study periods. However, these reported outcomes are based on this single pressure measurement (IOP) and do not directly measure long-term functional visual outcomes.

The Study Landscape: IOP Reduction as the Primary Focus

The research evidence primarily focuses on the IOP measure in conditions like POAG and OHT. This section details the types of scientific studies that have been conducted, including RCTs and Systematic Reviews.

Clinical trials initially focus on short-term outcomes, reporting primary endpoints after a few months. Researchers have conducted open-label extension studies and observational post-marketing surveillance to gather data on the measurements over extended periods, sometimes tracking them for one year, two years, and up to five years.

Understanding the Limits of the Evidence

While research is extensive, findings describe group patterns, not personal outcomes, and certain areas of research remain open or rely on established inferences.

The primary limitation is the focus on IOP as a single pressure measurement (IOP). The functional outcome of vision preservation is complex and remains a critical focus of long-term research. There is limited information for very long-term outcomes, and the relationship between short-term IOP changes and future functional outcomes is primarily inferred from general principles of glaucoma management.

Furthermore, comparative evidence is lacking in some scenarios, and for less common indications, the sample sizes were modest, meaning the evidence quality varies across studies. Research provides context but not individual predictions; findings describe group patterns, and the research does not determine whether an individual will respond similarly.

How should Xalatan be stored and disposed of?

Storage and Disposal of Xalatan

The storage of Xalatan (latanoprost ophthalmic solution) is strictly defined by regulatory requirements to ensure stability. Unopened bottles must be stored under refrigeration at a temperature range of 2 C to 8 C (36 F to 46 F) and kept in the original outer carton to protect the solution from light. The product must not be frozen.

Once the bottle is opened for use, it may be stored at room temperature up to 25 C (77 F). The in-use container must be kept tightly closed and must be discarded six weeks (42 days) after the date of first opening. Xalatan must be stored out of the sight and reach of children.

Disposal of unused or expired medicine must be done in accordance with local requirements. The medicine must not be thrown into wastewater or household trash to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.